Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CWP232228
- Development stage
- Preclinical
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
CWP232228 is a small molecule inhibitor of the Wnt/β-catenin signaling pathway, developed by JW Pharmaceutical. It acts by disrupting the interaction between β-catenin and T-cell factor (TCF) transcription factors, thereby inhibiting the expression of Wnt target genes involved in cell proliferation, survival, and stemness. Preclinical studies have demonstrated its efficacy in various malignancies, including epithelial ovarian cancer, breast cancer, and hepatocellular carcinoma, where it has been shown to induce apoptosis, inhibit cell migration and invasion, and reduce the population of cancer stem cells (CSCs).
02
Targets
CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on CWP232228.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CWP232228.